Learn how GenAI is transforming early drug discovery by designing novel, drug-like small molecules with improved potency, selectivity, and ADME properties.
Explore how GenAI integrates with synthesis planning and automation tools to prioritize viable candidates and accelerate iterative drug development.
Discuss how AI is used to identify pathological features, discover drug targets, and decode complex disease biology at a systems level.
Barry Cooks is a global enterprise technology veteran with 25 years of experience leading teams in cloud computing, hardware design, application microservices, artificial intelligence, and more. As Vice President of Technology at Amazon, he is responsible for compute abstractions (containers, serverless, VMware, micro-VMs), quantum experimentation, high performance computing, and AI training. He oversees key AWS services including AWS Lambda, Amazon Elastic Container Service, Amazon Elastic Kubernetes Service, and Amazon SageMaker. Barry also leads responsible AI initiatives across AWS, promoting the safe and ethical development of AI as a force for good. Prior to joining Amazon in 2022, Barry served as CTO at DigitalOcean, where he guided the organization through its successful IPO. His career also includes leadership roles at VMware and Sun Microsystems. Barry holds a BS in Computer Science from Purdue University and an MS in Computer Science from the University of Oregon.
